Magnetic Resonance Imaging to Detect Signs of Viral Pneumonia in Patients With Coronavirus Infection.

Sponsor
Research and Practical Clinical Center for Diagnostics and Telemedicine Technologies of the Moscow Health Care Department (Other)
Overall Status
Recruiting
CT.gov ID
NCT04424355
Collaborator
(none)
115
1
19.1
6

Study Details

Study Description

Brief Summary

Since the onset of the COVID-19 pandemic, the importance of chest computed tomography (CT) in detecting signs of viral pneumonia has become clear from the literature. However, the increased patient flow creates an additional pressure on CT centers. We believe, the use of chest magnetic resonance imaging (MRI) can help to test patients for CОVID-19 when CT scan is not available. Lung MRI may be useful in routing a patient in a difficult epidemiological situation.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Chest MRI

Detailed Description

Currently, with increased load of CT studies, alternative methods of viral pneumonia signs' visualization are required.

Investigators hypothesize that chest MRI could be a test for detecting pulmonary features of COVID-19. They consider using MRI to assess COVID-19 viral pneumonia. Absence of radiation exposure to patients is a clear advantage of MRI.

This is a prospective, observational cohort study assessing patients with suspected COVID-19. It's primary goal is to determine the ability of multiparametric MRI to detect lung abnormalities - ground-glass opacity (GGO), consolidation, "crazy paving" pattern, pleuritis

  • in comparison to CT scan. In this study each patient with suspected pneumonia will sequentially undergo both chest CT and MRI during his/her visit. Scan protocols will be identical for each patient. Each participants completed an online questionnaire.

Study Design

Study Type:
Observational
Anticipated Enrollment :
115 participants
Observational Model:
Cohort
Time Perspective:
Cross-Sectional
Official Title:
Possibilities of Chest Magnetic Resonance Imaging (MRI) in Diagnostics of COVID-19. The Use of MRI to Assess Lung Damage in Patients With Coronavirus Infection
Actual Study Start Date :
May 19, 2020
Anticipated Primary Completion Date :
Jul 19, 2021
Anticipated Study Completion Date :
Dec 20, 2021

Arms and Interventions

Arm Intervention/Treatment
Patients with suspected pneumonia COVID-19

Chest MRI findings: bilateral, diffuse ground-glass opacity (GGO), consolidation, "crazy paving" pattern, pleuritis.

Diagnostic Test: Chest MRI
Patients referred by the primary care physician with suspected pneumonia
Other Names:
  • Chest CT scan
  • Patients with suspected pneumonia with COVID -19

    Chest CT findings: bilateral, diffuse ground-glass opacity (GGO), consolidation, "crazy paving" pattern, pleuritis.

    Diagnostic Test: Chest MRI
    Patients referred by the primary care physician with suspected pneumonia
    Other Names:
  • Chest CT scan
  • Outcome Measures

    Primary Outcome Measures

    1. Number of zones of pulmonary parenchyma corresponding to viral pneumonia detected by chest MRI in comparison with CT scan [Upon completion, up to 1 year]

      Expected number - more than two zones

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • A referral from the attending physician for a chest CT scan

    • Suspected pneumonia

    • Signed informed consent

    • Over 18 years old

    Exclusion Criteria:
    • Pregnant or nursing women

    • Presence of foreign implanted objects in the body at the scan level (including cardiac pacemakers, spine metalware)

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Research and Practical Clinical Center for Diagnostics and Telemedicine Technologies of the Moscow Health Care Department Moscow Russian Federation 109029

    Sponsors and Collaborators

    • Research and Practical Clinical Center for Diagnostics and Telemedicine Technologies of the Moscow Health Care Department

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Sergey Morozov, Chief Research Officer, Research and Practical Clinical Center for Diagnostics and Telemedicine Technologies of the Moscow Health Care Department
    ClinicalTrials.gov Identifier:
    NCT04424355
    Other Study ID Numbers:
    • 2020-2
    First Posted:
    Jun 9, 2020
    Last Update Posted:
    Dec 10, 2020
    Last Verified:
    Dec 1, 2020
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Sergey Morozov, Chief Research Officer, Research and Practical Clinical Center for Diagnostics and Telemedicine Technologies of the Moscow Health Care Department
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Dec 10, 2020